Immunovaccine Inc. has signed a licensing deal with a Maryland biodefence company to develop and commercialize an anthrax vaccine. The Halifax vaccine developer announced the agreement with PharmAthene Inc. on Wednesday.
Immunovaccine could receive payments of up to $50 million if the product gets to market. The minimum amount the Halifax biotech firm will get from the United States anthrax developer is $200,000 per year during the development phase. Read the full article here: